{"id":13667,"date":"2020-07-11T21:12:12","date_gmt":"2020-07-11T15:42:12","guid":{"rendered":"http:\/\/udaen.info\/?p=13667"},"modified":"2020-07-11T21:12:12","modified_gmt":"2020-07-11T15:42:12","slug":"dcgi-approves-itolizumab-for-restricted-emergency-use-on-covid-19-patients","status":"publish","type":"post","link":"https:\/\/udaen.info\/?p=13667","title":{"rendered":"DCGI approves Itolizumab for restricted emergency use on COVID-19 patients"},"content":{"rendered":"<h2>DCGI approves Itolizumab for restricted emergency use on COVID-19 patients<\/h2>\n<div class=\"news-details-img\"><img decoding=\"async\" class=\"img-responsive img-right\" src=\"http:\/\/newsonair.com\/writereaddata\/News_Pictures\/NAT\/2020\/Jul\/NPIC-2020711203228.png\" \/>AIR Pics<\/div>\n<p>The Drugs Controller General of India has approved Itolizumab for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress syndrome.<\/p>\n<p>Drugs Controller General of India has approved Itolizumab injection for the treatment of &#8216;cytokine&#8217; release syndrome in moderate to severe acute respiratory distress syndrome in patients due to COVID-19. After satisfactory result from clinical trials, the drug was approved.<\/p>\n<p>Itolizumab injection is already an approved drug of Biocon Limited used for the treatment of patients with active moderate to severe psoriasis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DCGI approves Itolizumab for restricted emergency use on COVID-19 patients AIR Pics The Drugs Controller General of India has approved Itolizumab for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress syndrome. Drugs Controller General of India has approved Itolizumab injection for the treatment of &#8216;cytokine&#8217; release syndrome in moderate to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[74],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/13667"}],"collection":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13667"}],"version-history":[{"count":1,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/13667\/revisions"}],"predecessor-version":[{"id":13668,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/13667\/revisions\/13668"}],"wp:attachment":[{"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}